Students participate in SuperNOVA
Students at Dalhousie's SuperNOVA summer program put their remotely operated vehicles to the test.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
Article content – Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – Article content – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – Article content Article content – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – Article content – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – Article content SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Article content Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. Article content 'Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition.' Article content Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys ® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. Article content 'Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis,' said Matt Sause, CEO of Roche Diagnostics. 'Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families.' Article content Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Article content Pharmaceuticals Article content In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. Article content New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. Article content These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Article content Diagnostics Article content Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Article content Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys ® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys ® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Article content Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm – 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm – 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm – 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm – 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am – 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley Article content About trontinemab Article content Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. Article content The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. Article content About Roche in Alzheimer's Disease Article content With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. Article content About Genentech in Neuroscience Article content Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Article content Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. Article content Article content Article content Article content Article content
Globe and Mail
2 hours ago
- Globe and Mail
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: Company Has Received Over 10,000 Paid Pre-Orders for the FX Super One MPV as It Marks the 4th Anniversary of FFAI's Public Listing
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or the 'Company'), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Co-CEO of FF. This press release features multimedia. View the full release here: Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: Company Has Received Over 10,000 Paid Pre-Orders for the FX Super One MPV as it Marks the 4th Anniversary of FFAI's Public Listing 'This week marks the 4th anniversary of FFAI's public listing. Over the past four years, we've weathered countless ups and downs, pushed through our darkest hours, and stood firm in the face of doubts and challenges—never giving up. Above all, we are most grateful to the investors, stockholders, and partners who have stood by us. Your support is the reason our dream has never dimmed. As of the day of our July 17 Initial Product Launch of FX Super One, we have received over 10,000 paid pre-orders for this vehicle. Beyond the much-discussed Super EAI F.A.C.E., many people have asked me: what exactly are Super One's breakthroughs in product value for the U.S. market? To answer that, let's take a closer look at S2 and S3 Products & Technologies, where we've been carefully crafting. We've distilled five big breakthroughs in product value—these are what we believe give Super One its truly disruptive and differentiated edge in the U.S. market. First, it represents a whole new category—First Class EAI-MPV, addressing three key pain points for American users, including: Number one, traditional minivans may offer large interior space, but have poor power performance and safety, and offer no sense of luxury whatsoever. Number two, while the Escalade is luxurious, it's fundamentally constrained by its traditional, bulky SUV structure. This leads to a poor driving experience, inefficient use of space, and a compromised user experience overall. It's inconvenient to get in and out of and lacks the versatility for today's diverse lifestyles. Number three, let alone EAI capabilities, both of these vehicle types have almost zero AI capability and are stuck in a past era. We believe Super One is here to shatter old paradigms and deliver brand new value. Second, it is a vehicle EAI agent and an avatar of its owner. It redefines the human-vehicle relationship, moving from passive control to a partnership of mutual understanding and shared experience. It feels what you feel and accompanies where you go. Third, it delivers comprehensive intelligent active safety. Its high-strength steel body, electric AWD, and an AI risk prediction engine all work together to make every journey exceptionally safe and secure. Fourth, AI luxury and ultimate comfort like a private clubhouse, it breaks boundaries and sets new gold standards for luxury and comfort. Fifth, FF empowers the FX Super One with much of the core value of the $300,000 FF 91. With extreme price-to-performance ratio and running cost, it aims to bring accessible AI TechLuxury. S5: On capital markets and finance: After the July 17 launch, our Capital team organized a series of roadshows for investment institutions. We also had in-depth conversations with many investors online. A lot of investors are especially interested in our latest Web3 strategic partnership with HabitTrade, a well-known digital asset infrastructure platform. Many are excited about how FF, together with the Web3 industry, can once again generate eco chemistry and lead the next major trend in the industry. In fact, we've been researching and preparing in Web3 space for quite some time. We firmly believe that, with FF's unique AI and internet DNA, and by combining EAI mobility with Web3, blockchain technology, cryptocurrency, and stablecoin applications, we can create entirely new value for users and the industry. We're building a future where Web2 and Web3, on-chain and off-chain, the physical and virtual worlds, all come together. We look forward to sharing these exciting plans and updates with you soon. Thank you to all our investors for your continued attention and support for FF and FX. We'll keep driving the company's growth with open and transparent communication. Today we're starting with Government affairs updates in terms of S7 System and Capability Build-Up. This week, we brought the FX Super One and FF 91 to Capitol Hill in Washington, D.C. There, we held high-level closed-door discussions with over a dozen U.S. Congress members and tariff policy makers. We talked about important topics such as reshoring U.S. manufacturing, technological innovation, and industry policies related to tariffs—efforts that support the implementation of the Global Automotive Industry Bridge Strategy. After experiencing both models in person, the Congress members were very impressed. We believe we will fill a key gap in the market, upgrading the American consumer experience, and helping accelerate the reshoring of manufacturing and the advancement of the entire industry chain. But really, after the FX Super One's initial launch, this is only the beginning. The next crucial steps will be product delivery, a series of certification tests, and trial production. I'll be leading the team to give it our all in this new chapter—continuing our relentless execution. In August, we'll also be taking the FX Super One to the Pebble Beach Concours d'Elegance, the luxury car events. This fulfills the promise we made there last August, and we'll be sharing new outcomes from our bridge strategy. For us, attending Pebble Beach every year is not just about showcasing our products, it's about demonstrating our unwavering belief in making the impossible possible. We welcome friends and partners who are interested in joining us. See you next week.' ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF 91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes 'forward looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'plan to,' 'can,' 'will,' 'should,' 'future,' 'potential,' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding the Super One MPV, Super EAI F.A.C.E., and EAI Embodied AI Agent 6x4 architecture, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: the Company's ability to secure necessary agreements to license or produce FX vehicles in the U.S., the Middle East, or elsewhere, none of which have been secured; the Company's ability to homologate FX vehicles for sale in the U.S., the Middle East, or elsewhere; the Company's ability to secure the necessary funding to execute on its AI, EREV and Faraday X (FX) strategies, each of which will be substantial; the Company's ability to secure necessary permits at its Hanford, CA production facility; the Company's ability to secure regulatory approvals for the proposed Super One front grill; the potential impact of tariff policy; the Company's ability to continue as a going concern and improve its liquidity and financial position; the Company's ability to pay its outstanding obligations; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company's limited operating history and the significant barriers to growth it faces; the Company's history of losses and expectation of continued losses; the success of the Company's payroll expense reduction plan; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the Company's ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company's vehicles; current and potential litigation involving the Company; the Company's ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company's indebtedness; the Company's ability to cover future warranty claims; the Company's ability to use its 'at-the-market' program; insurance coverage; general economic and market conditions impacting demand for the Company's products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company's dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company's stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.
National Post
7 hours ago
- National Post
Bubba Wallace wins Brickyard 400 to become Indy's first Black winner
INDIANAPOLIS — Bubba Wallace became the first Black driver to win a major race on Indianapolis Motor Speedway's 2.5-mile oval, surviving a late rain delay, two overtimes, concerns over running out of fuel and a hard-charging Kyle Larson on Sunday in the Brickyard 400. Article content The third NASCAR Cup victory of Wallace's career was also his most significant — his first win at one of the series' four crown jewel races. Article content Article content It snapped a 100-race winless streak that dated to 2022 at Kansas. He also won at Talladega in 2021, but this milestone victory also gave him a playoff spot. No Black driver has won the Indianapolis 500, and Formula 1 raced on the track's road course. Article content 'Unbelievable,' Wallace shouted on his radio after crossing the yard of bricks. Article content And while the final gap was 0.222 seconds, he didn't reach victory lane without some consternation. Larson trailed by 5.057 seconds with 14 laps to go but the gap was down to about three seconds with six remaining when the yellow flag came out because of rain. The cars rolled to a stop on pit lane with four to go, giving Wallace about 20 additional minutes to think and rethink his restart strategy. Article content But after beating Larson through the second turn, a crash behind the leaders forced a second overtime, extending the race even more laps as Wallace's team thought he might run out of gas. Article content Wallace risked everything by staying on the track then beat the defending race winner off the restart again to prevent Larson from becoming the fourth back-to-back winner of the Brickyard. Article content Article content It also alleviated the frustration Wallace felt Saturday when he spent most of the qualifying session on the provisional pole only to see Chase Briscoe surpass with one of the last runs in the session. Article content He made sure there was no repeat Sunday, giving an added boost to the 23XI Racing co-owned by basketball Hall of Famer Michael Jordan and last week's race winner, Denny Hamlin, as it continues to battle NASCAR in court over its charter status. Article content The race inside the race — the In-Season Challenge — went to Ty Gibbs, who had a better car than Ty Dillon in qualifying and on race day. Gibbs finished 21st o win the inaugural March Madness-like single-elimination tournament and collect the $1 million prize. Article content Dillon, a surprise championship round entrant after making the field as the 32nd and final driver, finished 28th. Article content Three-time series champ Joey Logano appeared to have the edge with 26 laps to go until his right rear tire went flat. Though he was able to drive it into pit lane for a tire change, he lost power and struggled to get back on the track, knocking him out of contention. Article content Ryan Blaney held off Kyle Larson and Denny Hamlin to win the second stage, giving Blaney his fifth stage win of the year. Pole winner Chase Briscoe won the first stage, finishing ahead of Bubba Wallace and William Byron. It was Briscoe's second stage win of the season, his first since Pocono. Article content
